These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19488614)

  • 1. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis.
    Landim MB; Casella Filho A; Chagas AC
    Clinics (Sao Paulo); 2009 May; 64(5):471-8. PubMed ID: 19488614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
    Liu X; Xu X; Shang R; Chen Y
    Nitric Oxide; 2018 Aug; 78():113-120. PubMed ID: 29928990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R; Cibulka R; Rajdl D; Racek J
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
    Maas R
    Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
    Böger RH
    Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymmetric dimethylarginine--mechanisms and targets for therapeutic management.
    Vladimirova-Kitova LG
    Folia Med (Plovdiv); 2008; 50(1):12-21. PubMed ID: 18543783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
    Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
    Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine--an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction.
    McCarty MF
    Med Hypotheses; 2004; 63(4):699-708. PubMed ID: 15325021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Methylarginies-induced endothelial dysfunction in chronic kidney disease].
    Kimura K
    Yakugaku Zasshi; 2012; 132(4):443-8. PubMed ID: 22465920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homoarginine in the shadow of asymmetric dimethylarginine: from nitric oxide to cardiovascular disease.
    Papageorgiou N; Androulakis E; Papaioannou S; Antoniades C; Tousoulis D
    Amino Acids; 2015 Sep; 47(9):1741-50. PubMed ID: 26123985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
    Böger RH; Bode-Böger SM
    Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase.
    Hsu CP; Zhao JF; Lin SJ; Shyue SK; Guo BC; Lu TM; Lee TS
    J Am Heart Assoc; 2016 Apr; 5(4):e003327. PubMed ID: 27091343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
    Ueda S; Yamagishi SI; Matsumoto Y; Fukami K; Okuda S
    Clin Exp Nephrol; 2007 Jun; 11(2):115-121. PubMed ID: 17593510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-arginine analogs--inactive markers or active agents in atherogenesis?
    Surdacki A
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):302-11. PubMed ID: 18855643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
    Liu X; Hou L; Xu D; Chen A; Yang L; Zhuang Y; Xu Y; Fassett JT; Chen Y
    Nitric Oxide; 2016 Apr; 54():73-81. PubMed ID: 26923818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels.
    Uzun H; Konukoglu D; Besler M; Erdenen F; Sezgin C; Muderrisoglu C
    Clin Invest Med; 2008; 31(1):E1-7. PubMed ID: 18312743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine.
    Thum T; Tsikas D; Stein S; Schultheiss M; Eigenthaler M; Anker SD; Poole-Wilson PA; Ertl G; Bauersachs J
    J Am Coll Cardiol; 2005 Nov; 46(9):1693-701. PubMed ID: 16256870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.
    Lin KY; Ito A; Asagami T; Tsao PS; Adimoolam S; Kimoto M; Tsuji H; Reaven GM; Cooke JP
    Circulation; 2002 Aug; 106(8):987-92. PubMed ID: 12186805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.